Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Marcie TomblynDaniel J Weisdorf

Abstract

We compared the outcomes of 141 consecutive patients who received allogeneic transplantation with either myeloablative (MA) or nonmyeloablative/reduced intensity (NMA) conditioning for non-Hodgkin and Hodgkin lymphoma at the University of Minnesota. All patients were transplanted between 1997 and 2004. NMA transplant recipients were older and received umbilical cord blood grafts more frequently (MA: 6 [9%]; NMA: 33 [43%], P < .001). NMA patients had more advanced disease and 30 (39%) patients had undergone prior autologous transplantation. The 4-year overall survival (OS) (MA: 46% versus NMA: 49%; p = .34) and the 3-year progression-free survival (PFS) (MA: 44% versus NMA: 31%; P = 0.82) were similar after MA or NMA conditioning. However, MA conditioning resulted in significantly higher 1-year treatment-related mortality (TRM) (MA: 43% versus NMA: 17%; P < .01) but a lower risk of relapse at 3 years (MA: 11% versus NMA: 36%; P < .01). We conclude that similar transplant outcomes are achieved after allogeneic hematopoietic stem cell transplantation using MA conditioning in younger patients and NMA conditioning in older patients or those with prior autologous transplantation not eligible for MA conditioning. Modifications to refi...Continue Reading

References

Dec 13, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Roberto RodriguezStephen J Forman

❮ Previous
Next ❯

Citations

Jun 25, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Jieun Uhm, John Kuruvilla
Sep 29, 2011·Current Opinion in Oncology·Koen van Besien
Jan 22, 2013·American Journal of Clinical Oncology·Suzanne L WoldenUNKNOWN American Society for Radiation Oncology
Oct 4, 2008·Current Opinion in Hematology·Douglas R Adkins, John F DiPersio
Apr 24, 2015·Clinical and Experimental Immunology·C MeyerI Messaoudi
Sep 25, 2012·American Journal of Hematology·Arnold Freedman
Aug 19, 2011·American Journal of Hematology·Arnold Freedman
Aug 27, 2014·European Journal of Haematology·Jonathon B CohenVeronika Bachanova
Mar 17, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Miguel-Angel PeralesPaul A Carpenter
Apr 21, 2016·Translational Research : the Journal of Laboratory and Clinical Medicine·Kinjal SanghaviPamala A Jacobson
Mar 20, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Brian L McCluneDaniel J Weisdorf
Feb 8, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Thomas SheaUNKNOWN Cancer and Leukemia Group B
Dec 14, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gregory A HaleParameswaran N Hari
Feb 19, 2013·Journal of Clinical Epidemiology·Aurelien LatoucheJason P Fine
Mar 4, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jacopo MariottiPaolo Corradini
Apr 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Navneet S MajhailDaniel J Weisdorf
Nov 16, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marcie R TomblynGinna G Laport
Jan 27, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Claudio G BrunsteinJohn E Wagner
Nov 5, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Erica D WarlickDaniel J Weisdorf
Feb 23, 2021·Current Oncology·Mitchell SabloffRajiv Samant
May 28, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sairah AhmedMehdi Hamadani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.